Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of Brepocitinib in Healthy Subjects and Subjects With Plaque Psoriasis
NCT02310750Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2014
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of brepocitinib in plaque psoriasis (3 arms), sponsored by Pfizer. Primary endpoints: Change From Baseline in Blood Pressure at Day 28, Change From Baseline in Pulse Rate at Day 28 and 11 more. Started Nov 2014; status: completed.
02
Drugs
brepocitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02310750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02310750.